Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer

Table 1 Univariate and multivariate survival analysis for overall survival and recurrence-free survival in The Cancer Genome Atlas patients with hepatocellular carcinoma

Variables	Overall survival		Recurrence-free survival
	Relative risk (95%CI)	P value	Relative risk (95%CI)	P value
Univariate
Age (> 60 vs ≤ 60 yr)	1.17 (0.76-1.80)	0.48	1.33 (0.83-2.14)	0.24
Gender (female vs male)	1.21 (0.78-1.86)	0.39	0.91 (0.72-1.15)	0.44
Differentiation (Poorly vs well and moderately)	1.27 (0.83-1.95)	0.28	0.76 (0.48-1.21)	0.25
Residual tumor (R1 + R2 vs R0)	1.95 (0.94-4.06)	0.07	2.25 (1.02-4.98)	0.05
Child-Pugh classification (grade B vs A)	2.49 (1.21-5.12)	0.01	2.22 (0.95-5.19)	0.07
Vascular invasion (macro + micro vs none)	1.52 (0.94-2.46)	0.08	1.65 (1.00-2.71)	0.05
TNM staging (III + IV vs I + II)	2.39 (1.51-3.79)	< 0.001	4.32 (2.50-7.47)	< 0.001
Fibrosis (fibrosis + cirrhosis vs none)	0.98 (0.88-1.08)	0.63	0.81 (0.46-1.41)	0.45
AFP (≥ 200 ng/mL vs < 200 ng/mL)	1.15 (0.68-1.92)	0.61	0.85 (0.49-1.49)	0.58
PRDX1 expression (high vs low)	1.55 (1.01-2.36)	0.04	1.01 (0.63-1.60)	0.98
Inflammation in adjacent liver (severe + mild vs none)	1.20 (0.79-1.80)	0.39	1.30 (0.82-2.07)	0.26
Multivariate
Residual tumor (R1 + R2 vs R0)	-	-	0. 89 (0.28-2.89)	0.77
Child-Pugh classification (grade B vs A)	2.30 (1.10-4.78)	0.03	-	-
Vascular invasion (macro + micro vs none)	-	-	1.42 (0.79-2.55)	0.23
TNM staging (III + IV vs I + II)	2.36 (1.26-4.41)	0.007	5.04 (2.76-9.22)	< 0.001
PRDX1 expression (high vs low)	1.89 (1.07-3.36)	0.03	-	-

AFP: α-fetoprotein; PRDX1: Peroxiredoxin 1.